Login to Your Account

Dalcor CVOT moves along; seek dalcetrapib CETP win

By Randy Osborne
Staff Writer

Tuesday, March 7, 2017

With enrollment about six months ahead of schedule, Dalcor Pharmaceuticals Inc. has randomized more than 1,000 patients of the expected 5,000 for the phase III dal-Gene trial.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription